British scientists have discovered a new way of tackling the fatal parasitic disease African sleeping sickness which they say could pave the way for the development of safe, effective drugs to treat it.
The scientists, whose study was published in the journal Nature, said new drugs could be ready for human clinical trials in around 18 months.
"This is one of the most significant findings made in recent years in terms of drug discovery and development for neglected diseases," said Professor Paul Wyatt, director of the Drug Discovery for Tropical Diseases programme at Dundee University, who led the research.
The World Health Organisation estimates that between 50,000 and 70,000 people in sub-Saharan Africa are infected with the sleeping sickness, or human African trypanosomiasis (HAT), which is spread by the bite of the tsetse fly. Left untreated, it is usually fatal.
Wyatt said his team had discovered a compound that disrupts an enzyme called N-myristoyl transferase, or NMT, which is essential for the survival and growth of the parasites injected into the victim by the tsetse fly's bite.
Their study showed this NMT-inhibitor compound leads to rapid killing of trypanosomes in laboratory tests and cures trypanosomiasis in mice.
The disease, called sleeping sickness because of the disruption to the sleep cycle caused by parasites infecting the brain, has two stages, the second of which begins when the parasites have penetrated the central nervous system.
The second stage is particularly difficult to treat in poor rural areas where many victims live, the scientists said.
Of the two drugs currently available, one -- based on arsenic -- has fatal side effects in around one in 20 patients, and the other, eflornithine from Sanofi Aventis, requires prolonged hospital treatment and is not effective against all forms of the disease.
Increasing reports of treatment failures with these drugs have raised fears that soon there may be no effective treatment.
Wyatt said he hoped his team's research would change that.
"We now have a valid drug target for HAT and have found leads for drugs which can be dosed orally. These two findings represent significant strides in the development of a full-blown drug against sleeping sickness suitable for clinical trials."
African sleeping sickness is one of a group known as "neglected tropical diseases" which often struggle to attract research attention from large pharmaceutical firms.
These firms fear investment in research will not pay off as most sufferers live in poor countries and cannot afford to buy expensive medicines.
GlaxoSmithKline, Merck & Co, Pfizer and others recently announced new initiatives involving collaborating more closely in the search for treatments for neglected diseases.
Equipment donation to children's oncology institute is first project of state-run aid agency TIKA in Brazil
Some 450 other suspected cases seen in island nation; president says health workers are able to contain epidemic
UN says 900,000 doses of oral vaccine are to be given to Rohingya Muslims fleeing violence in neighboring Myanmar
3 cholera quarantine centers have been formed where victims are being treated
12 cases confirmed, 32 persons quarantined to halt spread of disease, says disease control body
Provided by UNICEF, vaccinations will be administered by public health officials in Syria’s Idlib province
Eggs tainted by the insecticide mostly originate from farms in those two countries but have since been found in 45 nations worldwide, the European health commissioner Vytenis Andriukaitisa said last week.
The UN says cholera is a major public health problem in the country with millions of cases registered every year. Last year, the disease claimed 817 lives there, according to the WHO.
The ministerial meeting will include representatives from some 30 countries, according to Canada's minister of environment and climate change, Catherine McKenna.
Cholera is endemic in Nigeria, with a rise in cases during rainy season from April to September, says disease control center
Police officers tested positive for cholera after eating infected food; health minister blames food workers
"Up to September 1, 14 deaths have been reported," the health ministry said in a statement, adding that "the total number of suspected cholera cases stands at 186."
Pharmaceutical company says treatment has more than 80 percent success rate for form of leukemia
Federal agency orders StemImmune to stop injecting vaccine into tumors of cancer patients
565,041 suspected cases of cholera have been recorded in the country since April 27
Unknown health risks include cancer, respiratory diseases, birth defects and reduced cognition